Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D T Beattie

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cephalalgia : an International Journal of Headache|May 1, 1997
Naratriptan: biological profile in animal models relevant to migraineH E Connor, W Feniuk, D T Beattie, et al.
Infection and Immunity|July 1, 1995
Heterologous antigen expression in Vibrio cholerae vector strainsJ R Butterton, D T Beattie, C L Gardel, et al.
Vascular Pharmacology|December 4, 2012
An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954D T Beattie, D L Higgins, M P Ero, et al.
Regulatory Peptides|August 27, 1996
GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activityC J Gardner, D R Armour, D T Beattie, et al.
British Journal of Pharmacology|February 13, 2007
A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptorsR G Vickery, N Mai, E Kaufman, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 15, 2008
The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activityD T Beattie, S R Armstrong, J P Shaw, et al.
British Journal of Pharmacology|December 1, 1995
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonistD T Beattie, I J Beresford, H E Connor, et al.
Journal of Medicinal Chemistry|January 1, 1991
Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotectionP Krogsgaard-Larsen, J W Ferkany, E O Nielsen, et al.
The Journal of Infectious Diseases|December 1, 1994
Development of a live, oral, attenuated vaccine against El Tor choleraD N Taylor, K P Killeen, D C Hack, et al.
The Journal of Infectious Diseases|October 1, 1995
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1J R Kenner, T S Coster, D N Taylor, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cephalalgia : an International Journal of Headache|May 1, 1997
Naratriptan: biological profile in animal models relevant to migraineH E Connor, W Feniuk, D T Beattie, et al.
Infection and Immunity|July 1, 1995
Heterologous antigen expression in Vibrio cholerae vector strainsJ R Butterton, D T Beattie, C L Gardel, et al.
Vascular Pharmacology|December 4, 2012
An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954D T Beattie, D L Higgins, M P Ero, et al.
Regulatory Peptides|August 27, 1996
GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activityC J Gardner, D R Armour, D T Beattie, et al.
British Journal of Pharmacology|February 13, 2007
A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptorsR G Vickery, N Mai, E Kaufman, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 15, 2008
The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activityD T Beattie, S R Armstrong, J P Shaw, et al.
British Journal of Pharmacology|December 1, 1995
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonistD T Beattie, I J Beresford, H E Connor, et al.
Journal of Medicinal Chemistry|January 1, 1991
Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotectionP Krogsgaard-Larsen, J W Ferkany, E O Nielsen, et al.
The Journal of Infectious Diseases|December 1, 1994
Development of a live, oral, attenuated vaccine against El Tor choleraD N Taylor, K P Killeen, D C Hack, et al.
The Journal of Infectious Diseases|October 1, 1995
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1J R Kenner, T S Coster, D N Taylor, et al.
Pageof 5